Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06549621

Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen Therapy

Carbon monoxide poisoning is a frequent domestic accident and the leading cause of death from unintentionnal poisoning. Its toxicity is based on the CO binding to hemoglobin and myoglobin, inhibition of mitochondrial cytochrome oxidase, resulting in tissue hypoxia and reduced adenosine triphosphate synthesis and ischemia-reperfusion injury.

This study aims to investigate the early and late cardiologic effects of CO in patients treated with hyperbaric oxygen (HBOT) for CO poisoning

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Carbon Monoxide Poisoning Cardiotoxicity Cardiovascular Diseases Chemically-Induced Disorders Drug-Related Side Effects and Adverse Reactions Gas Poisoning Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Poisoning Radiation Injuries Wounds and Injuries

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29909, France

Location status: Recruiting

Location contact

Anne Henckes

CONTACT

About this study

This is a single-center retrospective study on health data. The methodology includes a collection of data on health and history data of patients treated by HBOT fo CO poisoning between 01/01/2015 and 31/12/2021 and carrying out a telephone interview of patients who have had early cardiovascular manifestations of CO poisoning.

One month between the start of theses interviews, an information letter on the study is sent by post, giving the possibility of opposing it.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated for CO poisoning with HBOT in the hyperbaric and underwater medicine department of the Brest University hospital from 2015/01/01 to 2021/12/31

Exclusion criteria

  • refusal

Treatment and study plan

Primary outcomes

  1. early and late cardiac injury due to CO poisoning description

    Time frame: enrollment (inclusion)

    clinical manifestation, troponin elevation and/or ECG abnormality during acute CO poisoning description; then late cardiac manifestation and abnormality declared by patients who have had early cardiac abnormality (troponin elevation and/or ECG abnormalities)

Secondary outcomes

  1. relationship between the source of CO poisoning and cardiac injury

    Time frame: enrollment (inclusion)

    comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

  2. relationship between context of poisoning (domestic, professionnal or intentional poisoning) and cardiac injury

    Time frame: enrollment (inclusion)

    comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

  3. relationship between other possibly associated poisoning and cardiac injury

    Time frame: enrollment (inclusion)

    comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

  4. relationship between severity of neurological symptoms and cardiac injury

    Time frame: enrollment (inclusion)

    comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

  5. relationship between cardiovascular risk factors or preexisting cardio vascular abnormality and cardiac injury

    Time frame: enrollment (inclusion)

    comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

Study contacts

Contact information is provided by the study sponsor or research team.

anne Henckes

CONTACT

[email protected]

02 98 34 70 98

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: COCARDIOTOX

Important dates

Study start
2022
Primary completion
2022
Study completion
2024
First posted
Aug 12, 2024
Registry last updated
Aug 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.